Price T Rowe Associates Inc. MD Has $74.08 Million Stake in Krystal Biotech, Inc. $KRYS

Key Points

• Price T Rowe Associates Inc. MD reduced its holdings in Krystal Biotech, Inc. by 19.4% to 410,861 shares, valued at approximately $74.08 million, according to the latest SEC filing.
• Analysts have mixed ratings on Krystal Biotech with an average target price of $210.38; recent reports have ratings ranging from a "Strong Buy" to "neutral" with price targets between $166.00 and $240.00.
• Insider Suma Krishnan sold 13,435 shares of Krystal Biotech for over $2 million recently, indicating a 0.92% decrease in their ownership of the stock.

Price T Rowe Associates Inc. MD lowered its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 19.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 410,861 shares of the company's stock after selling 98,598 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 1.42% of Krystal Biotech worth $74,079,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brooklyn Investment Group raised its position in shares of Krystal Biotech by 291.7% during the first quarter. Brooklyn Investment Group now owns 141 shares of the company's stock worth $25,000 after acquiring an additional 105 shares during the last quarter. Fifth Third Bancorp raised its position in shares of Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after acquiring an additional 105 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Krystal Biotech during the first quarter worth $74,000. GF Fund Management CO. LTD. bought a new stake in shares of Krystal Biotech during the fourth quarter worth $95,000. Finally, GAMMA Investing LLC raised its position in shares of Krystal Biotech by 179.3% during the first quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after acquiring an additional 432 shares during the last quarter. Institutional investors own 86.29% of the company's stock.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 13,435 shares of the business's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $150.30, for a total value of $2,019,280.50. Following the completion of the transaction, the insider directly owned 1,443,276 shares of the company's stock, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 49,800 shares of company stock valued at $7,487,943 over the last ninety days. 13.70% of the stock is currently owned by insiders.

Krystal Biotech Stock Performance

NASDAQ:KRYS traded down $3.06 on Friday, reaching $147.70. The company's stock had a trading volume of 257,853 shares, compared to its average volume of 393,550. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $207.84. The firm has a market cap of $4.27 billion, a PE ratio of 30.02 and a beta of 0.66. The business's 50-day moving average price is $145.83 and its two-hundred day moving average price is $154.31.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The firm had revenue of $96.04 million during the quarter, compared to analysts' expectations of $95.42 million. As a group, sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analyst Ratings Changes

KRYS has been the subject of a number of recent research reports. Chardan Capital dropped their target price on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a research report on Friday, August 22nd. HC Wainwright reaffirmed a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research note on Friday, August 22nd. Guggenheim decreased their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Citigroup reaffirmed a "neutral" rating and set a $166.00 price objective (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Finally, Bank of America decreased their price objective on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, Krystal Biotech currently has an average rating of "Moderate Buy" and an average target price of $210.38.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).